Kuros Biosciences Ag Stock Net Income
| KURN Stock | CHF 25.24 0.24 0.96% |
As of the 15th of February 2026, Kuros Biosciences secures the Mean Deviation of 1.85, standard deviation of 2.55, and Risk Adjusted Performance of (0.03). Kuros Biosciences AG technical analysis lets you operate historical price patterns with an objective to determine a pattern that forecasts the direction of the firm's future prices. Please verify Kuros Biosciences mean deviation, standard deviation, information ratio, as well as the relationship between the coefficient of variation and variance to decide if Kuros Biosciences AG is priced some-what accurately, providing market reflects its recent price of 25.24 per share.
Kuros Biosciences Total Revenue |
|
Gross Profit | Profit Margin | Market Capitalization | Enterprise Value Revenue 9.4114 | Revenue |
| Last Reported | Projected for Next Year | ||
| Net Loss | -4.5 M | -4.7 M | |
| Net Loss | -4.3 M | -4.5 M | |
| Net Loss | -6.1 M | -6.4 M | |
| Net Loss | (0.09) | (0.09) | |
| Net Income Per E B T | 1.00 | 0.77 |
Kuros | Net Income |
The evolution of Net Income for Kuros Biosciences AG provides essential context for understanding the company's financial health trajectory. By analyzing this metric's behavior over time, investors can assess whether recent trends align with long-term patterns, and how Kuros Biosciences compares to historical norms and industry peers.
Latest Kuros Biosciences' Net Income Growth Pattern
Below is the plot of the Net Income of Kuros Biosciences AG over the last few years. Net income is one of the most important fundamental items in finance. It plays a large role in Kuros Biosciences financial statement analysis. It represents the amount of money remaining after all of Kuros Biosciences AG operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue. It is Kuros Biosciences' Net Loss historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Kuros Biosciences' overall financial position and show how it may be relating to other accounts over time.
| View | Last Reported (3.92 M) | 10 Years Trend |
|
Net Income |
| Timeline |
Kuros Net Income Regression Statistics
| Arithmetic Mean | (13,500,145) | |
| Geometric Mean | 11,694,736 | |
| Coefficient Of Variation | (74.60) | |
| Mean Deviation | 7,532,922 | |
| Median | (11,693,000) | |
| Standard Deviation | 10,071,573 | |
| Sample Variance | 101.4T | |
| Range | 40.3M | |
| R-Value | 0.53 | |
| Mean Square Error | 77.6T | |
| R-Squared | 0.28 | |
| Significance | 0.03 | |
| Slope | 1,061,367 | |
| Total Sum of Squares | 1623T |
Kuros Net Income History
Kuros Net Income Driver Correlations
Understanding the fundamental principles of building solid financial models for Kuros Biosciences is extremely important. It helps to project a fair market value of Kuros Stock properly, considering its historical fundamentals such as Net Income. Since Kuros Biosciences' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Kuros Biosciences' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Kuros Biosciences' interrelated accounts and indicators.
Click cells to compare fundamentals
Kuros Biosciences 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Kuros Biosciences' stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Kuros Biosciences.
| 11/17/2025 |
| 02/15/2026 |
If you would invest 0.00 in Kuros Biosciences on November 17, 2025 and sell it all today you would earn a total of 0.00 from holding Kuros Biosciences AG or generate 0.0% return on investment in Kuros Biosciences over 90 days. Kuros Biosciences is related to or competes with Idorsia, SKAN Group, COSMO Pharmaceuticals, Aevis Victoria, Basilea Pharmaceutica, Medartis Holding, and PolyPeptide Group. Kuros Biosciences AG, a biopharmaceutical company, engages in the discovery, development, and commercialization of bioph... More
Kuros Biosciences Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Kuros Biosciences' stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Kuros Biosciences AG upside and downside potential and time the market with a certain degree of confidence.
| Information Ratio | (0.07) | |||
| Maximum Drawdown | 14.6 | |||
| Value At Risk | (3.07) | |||
| Potential Upside | 5.38 |
Kuros Biosciences Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Kuros Biosciences' investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Kuros Biosciences' standard deviation. In reality, there are many statistical measures that can use Kuros Biosciences historical prices to predict the future Kuros Biosciences' volatility.| Risk Adjusted Performance | (0.03) | |||
| Jensen Alpha | (0.12) | |||
| Total Risk Alpha | (0.31) | |||
| Treynor Ratio | (105.34) |
Kuros Biosciences February 15, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | (0.03) | |||
| Market Risk Adjusted Performance | (105.33) | |||
| Mean Deviation | 1.85 | |||
| Coefficient Of Variation | (2,405) | |||
| Standard Deviation | 2.55 | |||
| Variance | 6.48 | |||
| Information Ratio | (0.07) | |||
| Jensen Alpha | (0.12) | |||
| Total Risk Alpha | (0.31) | |||
| Treynor Ratio | (105.34) | |||
| Maximum Drawdown | 14.6 | |||
| Value At Risk | (3.07) | |||
| Potential Upside | 5.38 | |||
| Skewness | 0.6458 | |||
| Kurtosis | 1.74 |
Kuros Biosciences Backtested Returns
Kuros Biosciences has Sharpe Ratio of -0.0304, which conveys that the firm had a -0.0304 % return per unit of risk over the last 3 months. Kuros Biosciences exposes twenty-three different technical indicators, which can help you to evaluate volatility embedded in its price movement. Please verify Kuros Biosciences' Mean Deviation of 1.85, risk adjusted performance of (0.03), and Standard Deviation of 2.55 to check out the risk estimate we provide. The company secures a Beta (Market Risk) of 0.0011, which conveys not very significant fluctuations relative to the market. As returns on the market increase, Kuros Biosciences' returns are expected to increase less than the market. However, during the bear market, the loss of holding Kuros Biosciences is expected to be smaller as well. At this point, Kuros Biosciences has a negative expected return of -0.0798%. Please make sure to verify Kuros Biosciences' maximum drawdown, potential upside, kurtosis, as well as the relationship between the value at risk and skewness , to decide if Kuros Biosciences performance from the past will be repeated at some point in the near future.
Auto-correlation | 0.48 |
Average predictability
Kuros Biosciences AG has average predictability. Overlapping area represents the amount of predictability between Kuros Biosciences time series from 17th of November 2025 to 1st of January 2026 and 1st of January 2026 to 15th of February 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Kuros Biosciences price movement. The serial correlation of 0.48 indicates that about 48.0% of current Kuros Biosciences price fluctuation can be explain by its past prices.
| Correlation Coefficient | 0.48 | |
| Spearman Rank Test | -0.03 | |
| Residual Average | 0.0 | |
| Price Variance | 1.02 |
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
Kuros Accumulated Other Comprehensive Income
Accumulated Other Comprehensive Income |
|
Based on the recorded statements, Kuros Biosciences AG reported net income of (3.92 Million). This is 101.15% lower than that of the Health Care Equipment & Supplies sector and 105.6% lower than that of the Health Care industry. The net income for all Switzerland stocks is 100.69% higher than that of the company.
Kuros Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Kuros Biosciences' direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Kuros Biosciences could also be used in its relative valuation, which is a method of valuing Kuros Biosciences by comparing valuation metrics of similar companies.Kuros Biosciences is currently under evaluation in net income category among its peers.
Kuros Fundamentals
| Return On Equity | -0.0862 | ||||
| Return On Asset | 0.0257 | ||||
| Profit Margin | (0.06) % | ||||
| Operating Margin | 0.06 % | ||||
| Current Valuation | 972.68 M | ||||
| Shares Outstanding | 39.18 M | ||||
| Shares Owned By Insiders | 27.83 % | ||||
| Shares Owned By Institutions | 23.40 % | ||||
| Price To Book | 12.90 X | ||||
| Price To Sales | 9.57 X | ||||
| Revenue | 75.56 M | ||||
| Gross Profit | 91.68 M | ||||
| EBITDA | (561 K) | ||||
| Net Income | (3.92 M) | ||||
| Cash And Equivalents | 18.33 M | ||||
| Cash Per Share | 1.22 X | ||||
| Total Debt | 1.79 M | ||||
| Current Ratio | 4.91 X | ||||
| Book Value Per Share | 1.90 X | ||||
| Cash Flow From Operations | 3.14 M | ||||
| Earnings Per Share | (0.15) X | ||||
| Target Price | 34.65 | ||||
| Number Of Employees | 158 | ||||
| Beta | 0.62 | ||||
| Market Capitalization | 988.78 M | ||||
| Total Asset | 84.54 M | ||||
| Retained Earnings | (45.43 M) | ||||
| Working Capital | 23.86 M | ||||
| Net Asset | 84.54 M |
About Kuros Biosciences Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Kuros Biosciences AG's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Kuros Biosciences using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Kuros Biosciences AG based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Kuros Stock Analysis
When running Kuros Biosciences' price analysis, check to measure Kuros Biosciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Kuros Biosciences is operating at the current time. Most of Kuros Biosciences' value examination focuses on studying past and present price action to predict the probability of Kuros Biosciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Kuros Biosciences' price. Additionally, you may evaluate how the addition of Kuros Biosciences to your portfolios can decrease your overall portfolio volatility.